DAVID LARRY INGRAM
Pilots at Newport Bay Dr, Indianapolis, IN
License number
Indiana A0917231
Issued Date
Dec 2015
Expiration Date
Dec 2017
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
7601 Newport Bay Dr UNIT 211, Indianapolis, IN 46240
Professional information
David Ingram, Indianapolis IN
Work:
University Pediatric Associates
702 Barnhill Dr, Indianapolis, IN 46202 University Pediatric Associates
4935 W Arlington Rd, Bloomington, IN 47404 Indiana University
1044 W Walnut St, Indianapolis, IN 46202
702 Barnhill Dr, Indianapolis, IN 46202 University Pediatric Associates
4935 W Arlington Rd, Bloomington, IN 47404 Indiana University
1044 W Walnut St, Indianapolis, IN 46202
Dr. David A Ingram, Indianapolis IN - MD (Doctor of Medicine)
Specialties:
Pediatrics
Address:
IU School Medcn Neonatology
699 Riley Hospital Dr STE RR208, Indianapolis 46202
(317) 274-4716 (Phone)
699 Riley Hospital Dr STE RR208, Indianapolis 46202
(317) 274-4716 (Phone)
Certifications:
Pediatrics, 2012
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Vanderbilt University
Graduated: 1993
In University School Of Med
University Ca Sf School Of Med
Vanderbilt University
Graduated: 1993
In University School Of Med
University Ca Sf School Of Med
Materials And Methods For Suppressing And/Or Treating Neurofibroma And Related Tumors
US Patent:
2011019, Aug 11, 2011
Filed:
Jun 25, 2009
Appl. No.:
12/996891
Inventors:
Wade D. Clapp - Indianapolis IN, US
David Ingram - Indianapolis IN, US
Feng-Chun Yang - Carmel IN, US
David Ingram - Indianapolis IN, US
Feng-Chun Yang - Carmel IN, US
International Classification:
A61K 31/496, A61P 25/00, A61P 35/00
US Classification:
51425218
Abstract:
Germline mutations in the NF1 tumor suppressor gene cause Von Recklinghausen's neurofibromatosis type 1 (NF1), a common genetic disorder of the nervous system characterized by plexiform neurofibroma development. Using adoptive transfer of hematopoietic cells, we establish that NF1 heterozygosity of bone marrow derived cells in the tumor microenvironment is sufficient to allow neurofibroma progression in the context of Schwann cell nullizygosity. Further, genetic or pharmacologic attenuation of the c-kit signaling pathway in hematopoietic cells greatly diminishes neurofibroma initiation and progression. These studies identify haploinsufficient hematopoietic cells and the c-kit receptor as therapeutic targets for preventing plexiform neurofibromas and implicate mast cells as critical mediators of tumor initiation. Administering therapeutically effective doses of a tyrosine kinase inhibitor such as the compound imatinib mesylate to a patient in need thereof to treat tumors in a human patient afflicted with plexiform neurofibroma.
Isolation, Expansion And Use Of Clonogenic Endothelial Progenitor Cells
US Patent:
2005026, Dec 1, 2005
Filed:
Feb 9, 2005
Appl. No.:
11/055182
Inventors:
Mervin Yoder - Indianapolis IN, US
David Ingram - Indianapolis IN, US
David Ingram - Indianapolis IN, US
International Classification:
C12N005/08
US Classification:
435372000
Abstract:
A hierarchy of endothelial colony forming cells (EPCs) was identified from mammalian cord blood, umbilical vein and aorta. A newly isolated cell named high proliferative potential—endothelial colony forming cell (HPP-ECFC) was isolated and characterized. Single cell assays were developed that test the proliferative and clonogenic potential of endothelial cells derived from cord blood, or from HUVECs and HAECs. EPCs were found to reside in vessel walls. Use of a feeder layer of cells derived from high proliferative potential-endothelial colony forming cells (HPP-ECPCS) from human umbilical cord blood, stimulates growth and survival of repopulating hematopoietic stem and progenitor cells. Stimulation of growth and survival was determined by increased numbers of progenitor cells in in vitro cultures and increased levels of human cell engraftment in the NOD/SCID immunodeficient mouse transplant system.
Blood Vessel Formation From Endothelial Colony Forming Cells
US Patent:
2008002, Jan 31, 2008
Filed:
Aug 13, 2007
Appl. No.:
11/837999
Inventors:
Mervin Yoder - Indianapolis IN, US
David Ingram - Indianapolis IN, US
Daniel Prater - Fishers IN, US
David Ingram - Indianapolis IN, US
Daniel Prater - Fishers IN, US
Assignee:
Indiana University Research and Technology Corporation - Indianapolis IN
International Classification:
A61K 35/12, A61P 9/00, C12N 5/02, C12N 5/08
US Classification:
424093700, 435325000, 435402000
Abstract:
Methods and compositions to form fully functional blood vessels in vivo using endothelial colony forming cells (ECFCs) are disclosed. Culturing ECFCs in a support material results in association of ECFCs in vitro and formation of blood vessels in vivo upon implantation. Direct administration of cultured ECFCs form blood vessels in vivo. Formation of blood vessels is useful in treating a variety of medical conditions including ischemia and hypoxia.
Diagnostics And Therapeutics Based On Circulating Progenitor Cells
US Patent:
2010020, Aug 12, 2010
Filed:
Feb 11, 2010
Appl. No.:
12/704275
Inventors:
David A. Ingram - Indianapolis IN, US
Myka L. Estes - Indianapolis IN, US
Daniel L. Prater - Indianapolis IN, US
Laura E. Mead - Indianapolis IN, US
Myka L. Estes - Indianapolis IN, US
Daniel L. Prater - Indianapolis IN, US
Laura E. Mead - Indianapolis IN, US
Assignee:
Indiana University Research and Technology Corporation - Indianapolis IN
International Classification:
A61K 39/395, C12Q 1/02
US Classification:
4241411, 435 29
Abstract:
Methods and compositions for detection, diagnosis, and therapeutics of arterial diseases based on pro-angiogenic and non-angiogenic circulating hematopoietic stem and progenitor cells (CHSPCs) and circulation endothelial colony forming cells (ECFCs) are described.